HC Wainwright Analysts Increase Earnings Estimates for Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Analysts at HC Wainwright boosted their FY2025 earnings per share estimates for shares of Esperion Therapeutics in a research report issued to clients and investors on Tuesday, November 7th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will earn $2.44 per share for the year, up from their prior estimate of $2.43. HC Wainwright currently has a “Buy” rating and a $22.00 price objective on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($1.95) per share. HC Wainwright also issued estimates for Esperion Therapeutics’ FY2026 earnings at $4.13 EPS and FY2027 earnings at $5.53 EPS.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. The firm had revenue of $33.97 million for the quarter, compared to analysts’ expectations of $30.84 million. During the same period in the prior year, the business posted ($0.81) earnings per share.

Other equities analysts have also recently issued research reports about the company. StockNews.com assumed coverage on Esperion Therapeutics in a report on Thursday, October 5th. They issued a “hold” rating for the company. Needham & Company LLC dropped their price target on Esperion Therapeutics from $9.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday. Finally, Northland Securities raised Esperion Therapeutics from an “under perform” rating to a “market perform” rating in a report on Tuesday, August 1st. Five analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Esperion Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.75.

Esperion Therapeutics Stock Performance

NASDAQ:ESPR opened at $0.88 on Thursday. The stock has a 50-day simple moving average of $1.04 and a two-hundred day simple moving average of $1.32. Esperion Therapeutics has a 52-week low of $0.70 and a 52-week high of $8.87. The firm has a market capitalization of $94.58 million, a PE ratio of -0.37 and a beta of 0.30.

Hedge Funds Weigh In On Esperion Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Chicago Partners Investment Group LLC acquired a new position in shares of Esperion Therapeutics in the 3rd quarter worth approximately $29,000. Simplicity Solutions LLC bought a new stake in shares of Esperion Therapeutics during the third quarter valued at about $30,000. Sei Investments Co. grew its position in Esperion Therapeutics by 78.7% during the first quarter. Sei Investments Co. now owns 20,979 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 9,242 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Esperion Therapeutics by 199.7% during the first quarter. Tower Research Capital LLC TRC now owns 20,907 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 13,932 shares during the period. Finally, Great West Life Assurance Co. Can raised its holdings in Esperion Therapeutics by 683.5% in the first quarter. Great West Life Assurance Co. Can now owns 23,552 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 20,546 shares in the last quarter. 69.76% of the stock is owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.